Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: inform (368), tell (481), alert (363), advise (652), warn (314), report (742)

Follow up after breast cancer - patient information

Description: This booklet explains what self-supported management is after treatment for early breast cancer and how it works.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Follow-up-after-breast-cancer-1107-PIL.pdf

Clofarabine

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CLOFARABINE In-Patient Regimen Clofarabine not licensed in adult patients. This may require funding Regimen • Acute
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Clofarabine.pdf

Guidance for new grant holders_June2022

Description: Guidance for new UHS* grant holders Congratulations, you’ve been awarded some research funding! Now what? What are the key thin
Url: /Media/Southampton-Clinical-Research/Downloads/Guidance-for-new-grant-holders-June2022.pdf

FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymphoma – FC PO (5 day)-Cyclophosphamide-Fludarabine PO
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf

Cyclophosphamide-Etoposide PO Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE ORAL Regimen Lymphoma – Cyclophosphamide-Etoposide PO Indication Palliative treatment of malignant lymphoma Toxicity Drug Adverse Effect
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Etoposide-PO-Ver-1.1.pdf

HSCTCyclophosphamide-Priming-1500

Description: Chemotherapy Protocol Haematopoietic Stem Cell Transplant (Autograft) CYCLOPHOSPHAMIDE PRIMING (1500mg/m2) Regimen • Haematopoietic Stem Cell Transplant (HSCT)- Cyclophosphamide Priming (1500mg/m2
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/hsctcyclophosphamide-priming-1500.pdf

HSCTCyclophosphamide Priming (1500)

Description: Chemotherapy Protocol Haematopoietic Stem Cell Transplant (Autograft) CYCLOPHOSPHAMIDE PRIMING (1500mg/m2) Regimen • Haematopoietic Stem Cell Transplant (HSCT)- Cyclophosphamide Priming (1500mg/m2
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTCyclophosphamide-Priming-1500.pdf

SOP setting up a new trial in shared care centre - 1 February 2013

Description: Paediatric Oncology UHSStandard Operating ProcedureOpening a New Trial in an Shared Care Centre (POSCU)SOP Number:
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/POSCU/SOP-Setting-up-a-new-trial-in-shared-care-centre-01-02-2013.pdf

My m health COPD

Description: in partnership with myCOPD | Asthma mymhealth.com Improve your knowledge Keep track of your condition Perfect yo
Url: /Media/UHS-website-2019/Docs/my-m-health-copd.pdf

Prostate cancer patient initiated follow-up - patient information

Description: This booklet explains what patient initiated follow-up (PIFU) for prostate cancer is and how it works.
Url: /Media/UHS-website-2019/Patientinformation/Surgery/Prostate-cancer-patient-initiated-follow-up-473-PIL.pdf

41 to 50 of 193

Previous … 3 4 5 6 7 … Next